Dr. Reddys Labs (RDY) Reports Q2 EPS of $0.27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Dr. Reddy’s Q2 and H1 FY17 Financial Results
October 25, 2016 6:37 AM EDT
Q2 Revenues at Rs. 35.9 Bn
(QoQ growth: 11%)
Q2 EBITDA at Rs. 6.4 Bn
(17.9% of Revenues)
H1 Revenues at Rs. 68.2 Bn
(YoY decline: 12%)
H1 EBITDA at Rs. 10.4 Bn
(15.2% of Revenues)
HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddys Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the second quarter and half year ended September 30, 2016 under International Financial Reporting Standards (IFRS).
Q2 FY17: Key Highlights
Revenues at Rs. 35.9 billion: QoQ growth: 11%... More